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AbstrACt
Objectives This study aims to identify the sources of 
funding for investigator-initiated clinical trials (IICTs) in 
Portugal, and to recommend ways to improve the quality 
of information collected from clinical trial databases about 
funding.
Design and methods A systematic search of trial 
registrations over the last 13 years—using the WHO 
International Clinical Trials Registry Platform (WHO-ICTRP) 
and four clinical trials registries (CTRs)—was carried out 
to identify IICTs in Portugal, used as a case study. Data 
from the databases were compared with data contained 
in publications to evaluate the consistency of information 
on funding sources. The term ‘database’ is used in this 
study to refer to both the WHO-ICTRP and the CTRs. When 
mentioned separately, the WHO-ICTRP is referred to as a 
‘platform’, while the CTRs are referred to as ‘registries’.
Outcome Suggestions to improve clinical trials databases 
to clearly identify the funding sources and data ownership 
in IICTs.
results Two hundred and eighty-two IICTs were identified 
in Portugal. Twenty per cent of trials were supported by 
industry with unclear information on the ownership of the 
results. Inaccuracy was found in the information about 
sponsors and funders. The information about funding in all 
resulting publications (77 out of 133 completed studies) 
was also inconsistent between databases in 35 out of 77 
(45%) of the studies. Notably, 23% of the trials funded 
by non-profit organisations (n=226) received funds from 
international and/or national funding agencies.
Conclusions Identification of IICT funding and ownership 
of results is unclear in the databases used for this 
study, which may lead to misunderstandings about the 
independence of the obtained results. Transparency and 
accuracy are desirable so that public decision makers 
and strategic partners can accurately evaluate national 
performance in this particular type of clinical research.
IntrODuCtIOn
Investigator-initiated clinical trials (IICTs), 
also referred to as non-commercial, academic 
or independent clinical trials, are generally 
sponsored by non-profit organisations. IICTs 
can also be supported by medicine or device 
companies, provided that they ensure that: 
(1) ownership of the results belongs to the 
sponsor–investigator and (2) no agreement 
exists limiting publication or allowing the use 
of data for regulatory or marketing purposes 
by industry.1 The design, conduct, recording 
and reporting of the clinical trial should be 
under the control of the sponsor–investigator.
IICTs attempt to answer relevant questions 
in clinical practice that may not otherwise 
be addressed by industry and may provide 
evidence to improve therapeutic guidelines 
and support clinical decisions. IICTs might 
include trials for the paediatric use of medi-
cines authorised for adults, or comparison 
of commercialised medicines. IICTs may 
also include pragmatic trials, and repur-
posing studies for novel indications for regis-
tered medicines, including in the field of 
rare diseases. Besides medicines, IICTs can 
address medical devices, nutrition, behaviour 
and surgery procedures to provide evidence 
on performance or the effect on health and 
well-being of participants. When compared 
strengths and limitations of this study
 ► Provides an analysis of the types of funding of inves-
tigator-initiated clinical trials (IICTs) for the first time, 
promoting discussion on the need for transparency.
 ► Compares information about funding sources con-
tained in clinical trials databases with that provided 
in publications.
 ► Provides the basis for specific recommendations to 
increase the quality of the information provided in 
databases.
 ► As a case study, data on funding sources are limited 
to studies initiated in Portugal. As such, the study 
may not be representative of other countries.
 ► The information on IICT funding (in the databases 
used) is incomplete, which may provide a partial or 
inaccurate portrait of results.
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with trials using medicines, other interventions are less 
demanding in terms of regulatory and ethical approvals.
In industry clinical trials, the funding source is the 
sponsor, whereas in non-commercial trials the sponsor 
might not be the funder. According to the Euro-
pean Regulation for clinical research (Regulation 
536/2014EC), the funds for these independent clinical 
trials might come partly or entirely from public funds or 
charities2 and the sponsor is generally the organisation 
that receives the funds. WHO Trial Registration Data Set 
(TRDS) defines the primary sponsor as the individual, 
organisation, group or other legal entity which takes 
responsibility for initiating, managing and/or financing 
a study, and for properly registering the trial; it may or 
may not be the main funder. In IICTs, the sponsor has 
the legal capability to establish contracts with individ-
uals (eg, principal investigator) or other stakeholders to 
assure the implementation and conduct of a clinical trial. 
When analysing all clinical trials in one database, during 
a specific timeframe, most of the trials testing medicines 
are mainly industry sponsored3 with commercial interests. 
On the other hand, according to the European Medi-
cines Agency, around 40% of trials registered in Europe 
are IICTs mainly sponsored by academia.4
The objective of this study was to identify the main 
funders of IICTs in Portugal (as a case study), and to make 
recommendations to improve the information collected 
from databases on the funding sources of these trials.
MethODs
We identified past or current IICTs registered and starting 
in one European country (Portugal) from 1 January 
2004 to 31 January 2017 in order to identify the funding 
source. Previously, we investigated trials that are ongoing 
in Portugal in only one database (EU Clinical Trials 
Register; EU-CTR).5 In the current study, we extended 
the number of databases used and the type of interven-
tion, considering the same country as a pilot.
The selection of clinical trials registries (CTRs) for 
this study was based on trials registered and recruiting in 
Portugal. We first screened the WHO International Clin-
ical Trials Registry Platform (WHO-ICTRP), a network 
platform that is directly updated by CTRs that comply with 
the required 24 quality-based items in the WHO-TRDS. 
This search enabled us to identify the presence of Portu-
guese trials in four of the main international registries: 
ClinicalTrials. gov, EU-CTR, International Standard 
Randomised Controlled Trial Number (ISRCTN) registry 
and the Australian New Zealand Clinical Trials Registry 
(ANZCTR).6
search methodology of trials in each database
Step 1
Our initial search in the WHO-ICTRP did not enable us 
to distinguish between commercial and non-commercial 
trials. Therefore, a general search was performed using 
the terms ‘Portugal and Interventional’ from the time 
period from 1 January 2004 to 31 January 2017.
Step 2
The search in the EU-CTR was performed by year (from 
1 January 2004 until 31 January 2017) with the terms 
‘Portugal and non-commercial’ in the general search 
field. The duplicates found in each year were sequentially 
identified and not considered for the total number.
Step 3
With the  ClinicalTrials. gov registry, it was not possible to 
distinguish between commercial and non-commercial 
trials. Therefore, an advanced search was performed 
selecting the options ‘Portugal’ and ‘Interventional 
studies’, and was limited to the above-mentioned time 
period.
Step 4
Registrations in the BiomedCentral CTR are associated 
with ISRCTN. In this CTR, it was not possible to refine 
the search besides selecting Portugal as the recruiting 
country. Trials initiated before or after the selected time-
frame were discarded.
Step 5
With the ANZCTR, we performed the search in the 
selected timeframe, using Portugal as the recruiting 
country. Registrations in this CTR have the initial code 
ACTRN.
In each of the above-mentioned search steps, all 
entries were manually screened, and trials sponsored 
by industry (ie, commercial trials) were not considered. 
Additionally, registrations were discarded when there 
were no recruiting sites in Portugal; duplications were 
detected (with only one of the entries conserved); trials 
were completed or registered before 2004; there were no 
patients enrolled; or no intervention was assigned (ie, 
observational trial) (see figure 1, Steps 1–5).
Data extraction
Step 6
 Information about trial identification (Trial ID) number—
main and secondary, recruitment status, sponsor name 
and country, and funding source—were extracted manu-
ally and independently from the registered records (from 
1 February 2017 to 31 March 2017) and organised in 
Excel sheets. Forty per cent of the records were double-
checked by two of the authors (CM and FS).
Sponsors were coded as being university, disease-spe-
cific organisation (disease associations or research insti-
tutes dedicated to a specific therapeutic area), hospital, 
research institute (non-specific therapeutic area), foun-
dation and other (eg, international funding agency and 
private health clinic).
Funders were coded as being (1) a non-profit organisa-
tion (eg, public institution, funding agency, disease-spe-
cific organisations), (2) a for-profit organisation (ie, 
private company/industry), (3) both, when funding was 
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provided by industry and non-profit organisation(s) and 
(4) not indicated, when the informationwas not provided. 
Information on funder type is indicated in the field enti-
tled ‘sources of monetary support’ in both WHO-ICTRP 
and EUCTR; in the ‘sponsor and collaborators’ field in 
ClinicalTrials. gov; and in the ‘funder’ field in ISRCTN 
and ANZCTR. When only the sponsor was mentioned 
in the  ClinicalTrials. gov registry, we considered it as 
the funder. Additionally, in this registry, the support of 
funding agencies was perceived through secondary IDs 
where the code of the grant agreement is in some cases 
added. Exclusive funding for PhD or postdoctoral grants 
was not considered.
Identification of duplicates and complementary information
Step 7
 All trials identified as non-commercial were added to the 
same Excel sheet and organised by sponsor name. Dupli-
cates were identified when secondary IDs were provided 
or when the sponsor and the title of the study were the 
same. Information obtained from different CTRs about 
Figure 1 Flowchart showing the systematic search of non-commercial clinical trials (ie, IICTs), involving Portuguese institutions 
recruiting participants. The search was performed in four clinical trial registries, clinical trials registries (CTRs) (EU Clinical Trials 
Register [EU-CTR], Clinicaltrials.gov, International Standard Randomised Controlled Trial Number (ISRCTN) and Australian 
New Zealand Clinical Trials Registry [ANZCTR]) and in the trial platform WHO International Clinical Trials Registry Platform 
(WHO-ICTRP). Studies starting from 1 January 2004 until 31 January 2017 were identified in each of the databases separately 
(Steps 1–5). After separating discarded and commercial studies, all remaining studies were gathered in one Excel sheet (Step 
6). Duplicate studies (Step 7), commercial studies or studies not recruiting in Portugal (Step 8) were not considered. The final 
number of trials was cleaned and harmonised, and further details were collected from all the databases (Step 9), including the 
identification of completed studies (Step 10). Publications with results from completed studies were identified (Step 11) and 
used to compare the information about funding sources provided in the CTRs and the published papers (link to Step 9).
 o
n
 30 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023394 on 14 May 2019. Downloaded from 
4 Madeira C, et al. BMJ Open 2019;9:e023394. doi:10.1136/bmjopen-2018-023394
Open access 
the same study was gathered in the final record (Step 9) 
and used for further analysis.
Step 8
A closer look at each registration allowed the identifica-
tion of more studies with no recruiting sites in Portugal as 
well as commercial trials.
Step 9
After removing duplicates or discarded trials, the data-
base with the final number of registrations was organised; 
information about funding was gathered when more than 
one registration was detected in Step 7.
search of publications of completed IICts
Step 10
Publications from the completed IICTs were manually and 
independently screened. The Trial ID was used to search 
abstracts of journals indexed in Medline (using PubMed) 
as well as the four CTRs. Other publications were also 
found through Google search using the study title or the 
Trial ID. Using the name of the principal investigator, it 
was possible to find publications about the study, when no 
paper was found with the previous strategies. Surprisingly, 
in some publications, the Trial ID was not included in the 
abstract, which rendered the search more difficult.
Step 11
Information about the funding source in each publication 
was manually and independently retrieved and compared 
with the information obtained from the databases by two 
of the authors (CM and FS).
Patient and public involvement
Neither patients nor the public were involved in this study.
results
A total of 2905 registrations were found in the four regis-
tries used ( ClinicalTrials. gov, EU-CTR, ISRCTN and 
ANZCTR) and the WHO-ICTRP. Trials were screened to 
isolate those with a non-commercial sponsor, recruiting 
sites in Portugal and a start date between January 2004 
and January 2017.
Identification of non-commercial studies
The number of trials identified in each database is shown 
in figure 1. After discarding industry-sponsored trials, 
non-interventional studies or those with no recruiting 
sites in Portugal, 601 non-commercial trials were consid-
ered eligible from all the screened databases. From 
those, 260 duplicates were identified, and 59 trials were 
discarded (figure 1). The main reason for the high 
number of discarded trials was that in the EU-CTR, the 
country is used as a general term. Therefore, registra-
tions with Portugal as (1) a planned country but not yet 
approved by competent authorities (n=18), (2) the owner 
of the marketing authorisation or (3) the producer of the 
medicine (n=27) were also detected.
As expected, a high number of trials was retrieved from 
the WHO-ICTRP (n=234, figure 1, Step 1) as this platform 
receives weekly updates of the registrations in each of the 
CTRs. Of the 234 trials found in the WHO-ICTRP, 224 had 
also been identified at least in one of the four CTRs; as 
such, they were considered duplicates (Step 7, figure 1). 
From the 224 trials in WHO-ICTRP, seven were found to 
be duplicates as they were registered in different CTRs 
with no secondary ID, which prevented WHO-ICTRP from 
considering that they were the same trial (Supplemen-
tary information 1 (S.I.1) figure 1, Step 9.2—see regis-
tries marked with **). Six of the additional trials found 
in WHO-ICTRP were not recruiting in Portugal or were 
commercial in nature, and were consequently discarded 
(Step 8). The four additional trials that were exclusively 
found in the WHO-ICTRP were retained for this study 
(Supplementary S.I.1 figure 1, Step 9.2). Surprisingly, 59 
registrations were found in the four CTRs but not in the 
WHO-ICTRP (Supplementary S.I.1 figure 1). This could 
be attributed to the methodology used for this study (eg, 
search terms: ‘Portugal and interventional’) as it is not 
possible to directly separate commercial from non-com-
mercial trials in the platform.
After separating the duplicated and discarded registra-
tions, 282 trials were further analysed; details are provided 
in Supplementary information 2 (S.I.2). The separation 
of the 282 trials registered in one, two or three CTRs 
(included or not in WHO-ICTRP) is shown in Supple-
mentary S.I.1 figure 1.
Information available in each database
In this study, we identified 282 IICTs among the nearly 3000 
registrations in the four CTRs used and WHO-ICTRP. We 
had to manually screen the trials to distinguish between 
commercial trials and non-commercial trials, as this was 
not a systematic search option in three of them. The 
ability to filter this information was better with EU-CTR 
and ANZCTR. In ANZCTR, the search may be performed 
by sponsor type with eight categories; in EU-CTR, it is 
possible to consider the option of commercial or non-com-
mercial study (figure 2A). Since September 2017, it has 
been possible to search trials according to the funder type 
in  ClinicalTrials. gov using the option ‘All others’, which 
includes non-profit organisations. Other differences in 
the information available in each database were ranked in 
terms of clearness according to our user experience. The 
evaluation is pictured in figure 2A, which clearly shows 
the need for improvement in the information provided, 
specifically in regards to non-commercial status, funding 
source and secondary ID.
Although ISCTRN and ANZCTR have a field where 
the name of the funder can be added, this informa-
tion is not mandatory. However, when compared with 
the other databases, these two clearly distinguish the 
sponsor from the funder with two separate fields for this 
purpose, and in 95%–100% of registrations the name of 
the funder is different from the sponsor (table 1).  Clini-
calTrials. gov only displays one field named ‘Sponsor and 
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collaborators’ that is not always consistent with the infor-
mation provided in the EU-CTR when the study is regis-
tered in both databases (Supplementary S.I.1 table 1). 
Collaborators were not indicated in 6% of registrations 
in  ClinicalTrials. gov, and in 51% of cases (where they 
were indicated), the collaborator was different from the 
sponsor (table 1). In the other CTRs, a higher percentage 
of registries had the funder different from the sponsor 
(68%–100%). The EU-CTR has a field entitled ‘Source(s) 
of monetary or material support for the clinical trial’, 
which might be ambiguous regarding the real origin of 
the financial resources and ownership of the results. For 
example, when the name of a private company is included 
in this field, it is not possible to know if this company is 
providing either financial support, medicines, or both, 
and who will be the owner of the obtained results: the 
private company or the investigator. Additionally, in 
around 52% of registrations in this CTR, no information 
about the funder was provided (table 1).
The majority of the trials (n=235) were registered 
in only one CTR (figure 2B), but when registered in 
different CTRs, the information about the trial was 
gathered in our records. Databases have a field to add a 
secondary ID but the information is not always provided 
(figure 2A) and only 12 out of 47 trials registered in more 
than 1 CTR include the secondary ID (see Supplementary 
S.I.1 table 2). The absence of secondary ID for the same 
trial gave rise to different records in the WHO-ICTRP 
(resulting in separate entries or duplicates).
Only 28% of trials registered in more than one CTR 
(13 out of 47) had consistent information about funding 
(inset of figure 2B) highest percentage (64%) of incon-
sistencies was detected when trials were registered in 
both  ClinicalTrials. gov and other CTR(s) (table 1). 
Figure 2 Comparison of information about funding and secondary ID between different clinical trials registries (CTRs) and 
WHO International Clinical Trials Registry Platform (WHO-ICTRP). (A) Characterisation of information provided in each database; 
(+++) the information was always explicitly provided, (++) the information was not always clearly provided and incongruences 
were frequently found, (o) clear and direct information was not provided. (B) Number of trials registered in one or more CTRs 
(EU Clinical Trials Register [EU-CTR], ClinicalTrials.gov, International Standard Randomised Controlled Trial Number [ISRCTN], 
Australian New Zealand Clinical Trials Registry [ANZCTR]). Inset: Consistency of the information about funding being provided 
by two or three CTRs, in the case where a study was registered in more than one CTR.
Table 1 Number of clinical trial registrations in each CTR, percentage of those identifying the funder as the sponsor or 
identifying the funder as different from the sponsor. Number of registrations with inconsistent information between the different 
CTRs
Clinical trial registry EU-CTR ClinicalTrials.gov ISRCTN ANZCTN
Name of the field with the funder identification in each CTR Source of Monetary 
or Material Support
Sponsor and 
Collaborators
Funder Funder
Total number of registrations 86 192 44 13
Registration without indication of Source of Monetary 
Support, Collaborator or Funder*
52% 6% 5% 0%
Clinical trials with funder/collaborator different from the 
sponsor*
68% 51% 95% 100%
Registration with inconsistent† information (Supplementary 
S.I.1 table 1)
12 out of 29
(41%)
21 out of 33 
(64%)
1 out of 8 
(13%)
0 out of 3 
(0%)
*Percentages calculated considering the total number of registrations indicated in the first line of the table.
†Inconsistent information means that information about funding source differed (with less information) from the others CTRs used for this 
study.
ANZCTR, Australian New Zealand Clinical Trials Registry; CTR, clinical trials registry; EU-CTR, EU Clinical Trials Register; ISRCTN, 
International Standard Randomised Controlled Trial Number.
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Inconsistencies may arise due to limitations in the fields 
provided by the registries; in  ClinicalTrials. gov, it is not 
possible to distinguish funders from collaborators (as 
this is a single field). However, collaborators might not 
necessarily be funders. This is the case, for instance, 
with trials funded by the European Commission (eg, 
NCT01802814), where collaborators are considered the 
beneficiaries of the EU-funded project.
Funders of non-commercial trials in Portugal
The analysis of sponsor organisation type showed that 
universities (n=139), disease-specific organisations 
(n=58) and hospitals (n=46) are the most frequent spon-
sors of non-commercial trials (figure 3A).
Industry was identified as the unique funding source in 
33 trials, while 24 studies were funded both by industry 
and non-profit organisations. It was not possible to iden-
tify the funder in 23 registered trials and the sponsor was 
considered as the funder in 79 registrations (mainly from 
ClinicalTrials. gov). In the end, 123 trials received funds 
exclusively from non-profit organisations. A more detailed 
analysis showed that a total of 51 trials received monetary 
support from national and international funding agen-
cies (figure 3B).
Among non-profit organisations, funding agencies are 
providing monetary support to 51 trials (23%), alone or 
together with other non-profit organisations (figure 3C). 
These trials are being funded by international funding 
agencies such as the European Commission, the British 
Medical Research Council and Spanish Carlos III Insti-
tute of Health, or by the national funding agency in 
Portugal: Portuguese Foundation for Science and Tech-
nology (FCT).
Consistency of information provided in databases and 
publications about funding of non-commercial trials
In this study, we identified that a total of 133 trials, corre-
sponding to 47% of the total number of trials, were 
completed (figure 4A). Only 77 of these trials have already 
been published. If, however, we consider trials completed 
by 2015, the percentage of trials published increases to 
60% (67 out of 111); this takes into account the 2 year, 
poststudy timeframe before publication.
Information about the funding source was screened 
in each publication, showing that 78% (60 out of 77) 
of these publications referred to the source of funds 
(figure 4B). Additionally, in 55% of the trials, the infor-
mation collected from the databases was consistent with 
the information provided in publications (even when no 
funding was mentioned in both), whereas in 20% of the 
trials, the publication provided additional information. 
However, in 25% of the trials (19 out of 77), the publica-
tion provided a funding source different from that indi-
cated in the databases (figure 4B).
Figure 3 Number of trials according to the type of sponsor (A), type of funding source (B) and type of non-profit organisation 
as funder (C). The category ‘Other’ in (A) includes a dental clinic and the National Health & Medical Research Council in 
Australia; and in (C) the category ‘Other’ includes foundations, private universities, clinics or health institutions.
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DIsCussIOn
In this study, a systematic analysis of IICTs registered in four 
CTRs and also in WHO-ICTRP was conducted with the 
main goal of understanding how these trials are funded in 
Portugal, used as a case study. The search was not straight-
forward and several incongruences were found after a labo-
rious and time-consuming process of screening each of the 
282 registered non-commercial clinical trials.
Several IICTs (16%; n=47) were registered in different 
CTRs but secondary IDs were not always provided (Supple-
mentary S.I.1 table 2). Surprisingly, for the same study, 
information about funding was not consistent in 72% 
of cases (or 34 out of 47) when trials were registered 
in more than one CTR (figure 2B and Supplementary 
table 1). Higher numbers of inconsistencies were found 
in registrations in  ClinicalTrials. gov when compared with 
the other CTRs (table 1). Even WHO-ICTRP, as previously 
indicated by others, does not reliably identify trials listed 
in multiple CTRs, making manual searches necessary.7 8 
We cannot explain the fact that some registrations in the 
screened CTRs were not detected in the WHO-ICTRP 
search, even though it was a broad search. Moreover, it is 
also not possible to explain why some registrations found in 
the CTRs were still not identified in the WHO-ICTRP when 
the ID number was searched directly (eg, NCT01280929, 
NCT01281098, NCT00189553, NCT00561054).
Raftery et al showed the number of UK non-commer-
cial trials registered by funding source from 1990 to 
2009 and emphasised the fact that the trials registered 
in  Clinicaltrials. gov had an unknown funding source.9 
Our findings are fully in line with these authors’ views 
and herein we reiterate the need to improve the infor-
mation about the funding source and the ownership of 
the results in  Clinicaltrials. gov. We believe that this is a 
way to increase the quality of records and the transpar-
ency of results of non-commercial trials. The inclusion 
of the funding source in  Clinicaltrials. gov was one of 
the requirements for the Proposed Rule by Title VIII of 
the Food and Drug Administration Amendments Act of 
200710 and it is mandatory in the TRDS for CTRs that 
provide information to the WHO-ICTRP. Nevertheless, 
to date, the clear identification of the funders and inde-
pendence of results from commercial interests have not 
been considered as criteria when discussing the need for 
improvement of the available databases.
Inconsistencies were also found when comparing infor-
mation about funding sources in CTRs and publications 
of completed IICTs. Publications are not necessarily listed 
on trial registries, requiring an extensive manual effort to 
Table 2 Limitations and recommendations for improving 
accuracy of clinical trial databases
Current limitations in the 
use of databases (CTRs and 
WHO-ICTRP) for identifying 
non-commercial trials
Suggested strategies for 
improvement
The identification of non-
commercial trials in registries 
is a laborious and time-
consuming task
Create a field in these 
databases allowing the 
separation of these trials 
from commercial trials, 
following the example of EU-
CTR
Registration of the same 
study in different databases 
provide different information 
about the funding source 
(table 1)
Make it a registration 
requirement in all databases 
to provide information about 
the (i) funding source, (ii) 
the role of the investigator 
and the funder in the design 
of the study and (iii) the 
ownership of the results
When industry is the funder 
it is not possible to have 
information about the 
ownership of the results, 
unless the study is published
With WHO-ICTRP some 
trials registered in different 
CTRs are not identified as 
duplicates7 8
Improve this platform for 
detection of duplicates using 
not only the secondary ID but 
also the title of the study and 
the name of the sponsor
CRTs, clinical trials registries; EU-CTR, EU Clinical Trials Register; 
WHO-ICRP, WHO International Clinical Trials Registry Platform.
Figure 4 Completed clinical trials. (A) Comparison between the number of completed investigator-initiated clinical trials 
(n=133) and those that were published (n=77); (B) comparison of the information about funding source collected from 
publications with the information provided in the relevant database(s).
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identify them. In 45% (35 out of 77) of the publications on 
completed IICTs (figure 4B), the information provided is 
not consistent with the CTR: a different funding source 
is referred to and/or additional information is provided. 
Although some journals already require the full disclo-
sure of funders and their input on the study, a harmon-
isation of editorial policies concerning this issue should 
be implemented by all publishers, because in some jour-
nals, funding is not even mentioned. In the publication of 
IICTs, mainly those using medicines or medical devices, 
a statement of the independence of researchers from 
industry funders should be mandatory.
In Portugal, although 18% of IICTs (51 out of 282) 
are being funded by funding agencies, 35% of trials are 
funded by a national public institution (mainly universities, 
see figure 3). On the other hand, 20% (57 out of 282) of 
IICTs have received support from the industry (figure 3B). 
Even though this support could be money or other type, 
when the study is funded or supported by a pharmaceu-
tical company it is not clear who will be the owner of the 
obtained results. If the owner is the private company, the 
study should not be labelled as an IICT. Currently, through 
the screened databases, it is not possible to confirm if the 
ownership of the results belongs to the investigators when 
the funder is a pharmaceutical company. As suggested by 
others, public CTRs should ensure adequate monitoring of 
trial registrations; this would ensure completion of manda-
tory contact information fields identifying scientific leader-
ship to promote accountability and transparency in clinical 
trial research.11 In some cases, information about scientific 
leadershipis only clear when the results are published in 
scientific journals in which the ownership of the trial design 
and results is claimed by the clinical investigators involved 
in the study.12 It would be important to add this informa-
tion in the registration phase to ensure that questions over 
funding do not have a negative effect on the use of IICT-
findings on the definition of new public health policies and 
implementation of new therapeutic approaches.
In this study, a systematic analysis of the information 
provided by the sponsor about the funding source is 
presented for the first time in order to clearly identify IICTs. 
When searching the five databases, we faced several limita-
tions and suggest the following strategies for improving the 
accuracy of clinical trial databases (table 2).
National competent authorities and/or Ethics Commit-
tees might also have a contribution to make to increase 
transparency in IICTs. This could be achieved by making 
it mandatory to fully complete the registration of the 
study before it is approved, including information about 
the funder and ownership of results.
COnClusIOns
Although major progress has been made in recent years 
regarding clinical trial registration, we show here that the 
most frequently used CTRs are still lacking in complete-
ness and consistency of information. In addition, the 
process of distinguishing commercial clinical trials from 
IICTs is not straightforward. Simplifying the identifica-
tion process of IICTs through the databases would facil-
itate a direct and clear comparison of performance in 
each country in terms of the quality of the trials; it would 
also help to identify the possible funding sources avail-
able to investigators.
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